Recent advances in understanding and managing leiomyosarcomas.

Recent advances in understanding and managing leiomyosarcomas. F1000Prime Rep. 2015;7:55 Authors: Duffaud F, Ray-Coquard I, Salas S, Pautier P Abstract Leiomyosarcomas are malignant mesenchymal tumours that derive from the smooth muscle lineage. They are studied and frequently treated as if they are the same as other soft tissue sarcomas. Recent developments suggest that a different approach may be more appropriate. Their underlying genetic mechanisms remain unclear, and complex. Unbalanced karyotypic defects are the only shared features observed across different leiomyosarcoma subtypes. Unlike other soft tissue sarcomas, leiomyosarcomas are particularly sensitive to the combination of gemcitabine and docetaxel. Furthermore, treatment with trabectedin has shown a good efficacy in leiomyosarcomas, mainly in the form of chronic disease stabilisation. PMID: 26097728 [PubMed - as supplied by publisher]
Source: F1000 Medicine Reports - Category: Biomedical Science Tags: F1000Prime Rep Source Type: research